Literature DB >> 21872791

Primary hyperaldosteronism: expanding the diagnostic net.

Sylvia Djajadiningrat-Laanen1, Sara Galac, Hans Kooistra.   

Abstract

PRACTICAL RELEVANCE: Primary hyperaldosteronism is probably the most common adrenocortical disorder in cats. As in humans, it is often unrecognised, which excludes a potentially large number of cats from appropriate treatment. PATIENT GROUP: Affected cats present at a median age of 13 years (range 5-20 years). A breed or sex predilection has not been documented. The excessive secretion of mineralocorticoids usually leads to hypokalaemia and/or systemic arterial hypertension. Most affected cats present with muscular weakness and/or ocular signs of arterial hypertension. DIAGNOSTICS: In any cat presenting with hypokalaemia and/or arterial hypertension, other potential causes should be excluded. The ratio of plasma aldosterone concentration to plasma renin activity (aldosterone:renin ratio) is currently the best screening test for feline primary hyperaldosteronism. Diagnostic imaging is required to differentiate between adrenocortical neoplasia and bilateral hyperplasia, and to detect any distant metastases. CLINICAL CHALLENGES: The differentiation between adrenocortical neoplasia and bilateral hyperplasia is imperative for planning optimal therapy, but the limited sensitivity of diagnostic imaging may occasionally pose a problem. For confirmed unilateral primary hyperaldosteronism, unilateral adrenalectomy is the treatment of choice, and offers an excellent prognosis, but potentially fatal intra- and postoperative haemorrhage is a reported complication and risk factors have yet to be identified. EVIDENCE BASE: Only a few case reports are available on which to base the optimal diagnostic and therapeutic approach to feline primary hyperaldosteronism. This article reviews the physiology of aldosterone production and the pathophysiology of primary hyperaldosteronism, and summarises the currently available literature on the feline disease. Practical suggestions are given for the diagnostic investigation of cats with suspected primary hyperaldosteronism.
Copyright © 2011 ISFM and AAFP. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21872791     DOI: 10.1016/j.jfms.2011.07.017

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  7 in total

1.  Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease.

Authors:  Yushi Zhang; Hanzhong Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Concomitant multiple myeloma and probable phaeochromocytoma in a cat.

Authors:  Mario Cervone
Journal:  JFMS Open Rep       Date:  2017-07-21

3.  Hydrocortisone therapy in a cat with vasopressor-refractory septic shock and suspected critical illness-related corticosteroid insufficiency.

Authors:  Simone R R Pisano; Judith Howard; Horst Posthaus; Alan Kovacevic; Ivayla D Yozova
Journal:  Clin Case Rep       Date:  2017-05-31

4.  Adrenocortical tumor in a cat secreting more than one type of corticosteroid.

Authors:  Simone Domit Guerios; Carlos Henrique de Melo Souza; Nicholas J Bacon
Journal:  JFMS Open Rep       Date:  2015-12-01

5.  Acute adrenal haemorrhage in two cats with aldosterone-secreting adenocarcinomas.

Authors:  Nicolle Kirkwood; Lara Boland; Laurencie Brunel; Alison Wardman; Vanessa R Barrs
Journal:  JFMS Open Rep       Date:  2019-04-03

6.  A case of behavioral changes in a castrated male cat due to a functional adrenocortical adenoma producing testosterone and androstenedione.

Authors:  Archivaldo Reche Junior; Daniela Ramos; Mariana Ferreira; Luís Artur Gp da Silva; Yumi Hirai; Pedro V Horta
Journal:  JFMS Open Rep       Date:  2021-01-12

7.  Treatment of aldosterone-secreting adrenocortical tumors in cats by unilateral adrenalectomy: 10 cases (2002-2012).

Authors:  A J Lo; D E Holt; D C Brown; M D Schlicksup; R J Orsher; K A Agnello
Journal:  J Vet Intern Med       Date:  2013-12-26       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.